Press Releases
-
Innovative SILAC-Based Proteomics Analysis Service Launched by Creative Proteomics
Oct 29, 2023
-
Revolutionizing Metabolomics: Creative Proteomics Unveils LC-MS/MS Untargeted Metabolomics Service
Oct 15, 2023
-
Creative Proteomics Introduces Methionine Cycle Analysis Service for Metabolomics Research
Oct 4, 2023
-
Phastar Offers Pro Bono Support to Medicines Development for Global Health
Phastar Offers Pro Bono Support to Medicines Development for Global Health Supporting medicine development for disadvantaged communities
Oct 25, 2023
-
Catawba Research Announces the Promotion of Andrew Silverman, Ph.D., to CEO
Catawba Research, a leading clinical research organization with a goal to become the world’s most trusted CRO, is announcing changes to its executive leadership team.
Oct 25, 2023
-
BioIVT Expands its Biospecimen Portfolio in Support of Neuroscience Research
BioIVT will be available to discuss its newly expanded, comprehensive portfolio of neuro-related disease and TruNormal® biospecimens at Neuroscience 2023.
Oct 26, 2023
-
MIB Agents Now Accepting Applications for Annual OutSmarting Osteosarcoma Research Grants
Oct 25, 2023
-
Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand
Oct 25, 2023
-
Maximizing Therapeutic Potential: CD Formulation's Versatile Drug Delivery Systems Advance Pharmacokinetics and Pharmacodynamics
Oct 25, 2023
-
Elligo and Avallano Launching Patient-First, AI-Powered Clinical Trials Ecosystem
Elligo Health Research®, the largest healthcare-enabling research organization, today announced a partnership with Avallano, a data privacy and healthcare technology company, to launch myTrialsConnectSM, a scalable research community powered by artificial intelligence (AI), that was built to serve patients, providers, sites, and the biopharma industry.
Oct 25, 2023
-
Elemental, Ions and Water (Karl Fischer) Standards Make Analytical Testing More Accurate and Easier
Oct 25, 2023
-
Samsung Biologics reports third quarter 2023 financial results
Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization (CDMO), today announced financial results for the third quarter of fiscal year 2023.
Oct 24, 2023
-
Amerigo Scientific Unveils CRISPR/Cas Enzymes to Expand the CRISPR Toolbox
Oct 23, 2023
-
Securing the Integrity of Microneedle Structure Design and Optimization: CD Formulation's Performance Testing Approach
Oct 23, 2023
-
Profacgen Updated Its Electrophoretic Mobility Shift Assay (EMSA) Service
Oct 23, 2023
-
Creative BioMart Provides a Wide Range of Biomarker Proteins for Research Use
Oct 23, 2023
-
CD BioGlyco Releases One-Stop Services for Glycoprotein-Based Vaccine Development
Oct 23, 2023
-
Alfa Chemistry Announces the Launch of Innovative IVD Products for Laboratory Use
Oct 23, 2023
-
Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma’s portfolio companies
Oct 22, 2023
-
Creative Biolabs Unveils ADC Services, Igniting Excitement in the Biotech Industry
Creative Biolabs, a prominent provider of groundbreaking biotechnology solutions, proudly announced the expansion of its antibody-drug conjugate (ADC) business with the introduction of novel services.
Oct 22, 2023






